A new optically pure synthon, precursor of the ω chain, was applied for synthesis of Travoprost (Fig.1), which is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. [1]

Fig 1. Travoprost, namely izopropyl (Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(R,E)-3-hydroxy-4-(3-trifluoromethylphenoxy)but-1-enyl]cyclopentyl}hept-5-enoate

Synthesis of the new ω chain  synthon consisted of seven optimized synthetic steps. Identity and  enantiomeric purity of the synthesized compounds were determined.

Determining the enantiomeric purity of chiral therapeutic agents is important in the development of active pharmaceutical ingredients (API).  Analytical method used for this purpose must ensure fast and effective separation of isomers. The common and widely applied method which meets these requirements is high performance liquid chromatography (HPLC).

The HPLC methods for determination of investigated compounds were developed. The individual compounds were separated using columns containing polysaccharide chiral stationary phase. The mobile phase consisted of hexane with addition of an alcohol (methanol, ethanol or  isopropanol). UV detection with detector  wavelength was  220 nm was applied to determine the investigated compounds. In course of extensive research it was proven, that the developed methods are selective and sensitive for all separated compounds. Elaborated method fulfills the criteria of European Pharmacopoeia for API analysis and can be used to control the synthesis process. [2][3]

[1]   leki-nformacje.pl

[2]   www.usp.org

[3] European Directorate for the Quality of Medicines & HealthCare, European Pharmacopoeia 7.0, Chapter: 2.2.46 Chromatographic separation techniques (2010)

Projekt współfinansowany przez Unię Europejską z Europejskiego Funduszu Rozwoju Regionalnego w ramach Programu Operacyjnego Innowacyjna Gospodarka

nr UDA-POIG.01.03.01-14-068/08-00 „Opracowanie innowacyjnych technologii leków oftalmicznych o szczególnym znaczeniu terapeutycznym i społecznym”

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/28051 must be provided.

1. Elaboration of travoprost eye drops formulation.
2. Determination of organic volatile impurities in Nepafenac by GC method
3. Application of the new data processing method for photodiode array detector in the analysis of drug substances
4. Validation of HPLC methods for analyzing the chemical purity of cilostazol
5. Identification of degradation products of cilostazol drug substance
6. A novel convergent synthesis of the prostaglandin F_2α analogues
7. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
8. Comparative permeation studies of tacalcitol through the human skin from brand product versus generic product
9. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
10. HPLC methods for in–process control and chemical purity determination of olopatadine
11. An improved process for the preparation of 2-amino-N-tert-butyl-2-cyanoamide hydrochlorie.
12. Development and validation of HPLC method. Review of selected cases.
13. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
14. Experimental and theoretical charge density studies on a model analogue of vitamin D
15. Analytical control of synthesis and determination of BR-S by HPLC
16. Optimization of BR-8 synthesis
17. Opimisation of preparation of TZ-6
18. HPLC method as an analitycal control of synthesis and determination of TZ-S
19. The synthesis of ezetimibe with high stereochemical purity
20. Validation of a HPLC method for LI-S analysis
21. A novel synthesis of 19-nor analogs of vitamin D
22. Zolmitriptan synthesis and in-process control by HPLC methods
23. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
24. New rosiglitazone salts
25. High-yielded method of synthesis of voriconazole.
26. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
27. HPLC AS A METHOD FOR ANALYTICAL CONTROL OF SYNTHESIS AND DETERMINATION OF PRAMIPEXOLE
28. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES